NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

醫藥品連續生產的全球市場:2021-2028年

Global Pharmaceutical Continuous Manufacturing Market Forecast 2021-2028

出版商 Inkwood Research 商品編碼 987556
出版日期 內容資訊 英文 205 Pages
商品交期: 2-3個工作天內
價格
醫藥品連續生產的全球市場:2021-2028年 Global Pharmaceutical Continuous Manufacturing Market Forecast 2021-2028
出版日期: 2021年02月08日內容資訊: 英文 205 Pages
簡介

全球醫藥品連續生產的市場規模在預測期間內預計以10.23%的年複合成長率成長。醫藥品連續生產系統的引進擴大,推動連續生產系統的採用的政府配合措施,新興市場開發機會,高分子藥及生技藥品的生產量增加,醫療費的擴大等要素促進該市場的成長。

本報告提供全球醫藥品連續生產的市場調查,市場定義和概要,新型冠狀病毒感染疾病 (COVID-19) 以及其他的市場影響因素分析,法律制度,市場規模的變化、預測,產品、用途、終端用戶、地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等彙整資訊。

第1章 調查範圍、調查手法

第2章 摘要整理

  • 市場規模、估計
  • 市場概要

第3章 市場動態

  • 主要的成長推動因素
  • 主要的規定

第4章 主要分析

  • 波特的五力分析
  • COVID-19的影響
  • 法律規範
  • 市場機會矩陣
  • 業者情勢
  • 投資分析

第5章 市場分析、預測:各產品

  • 整合型連續系統
  • 半連續系統
  • 控制、軟體

第6章 市場分析、預測:各用途

  • 最後醫藥品製造
  • API製造

第7章 市場分析、預測:各終端用戶

  • 製藥企業
  • CMO
  • 其他

第8章 市場分析、預測:各地區、主要國家

  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第9章 競爭情形

  • 主要策略的展開
  • 企業簡介
    • COPERION GMBH
    • ELI LILLY & COMPANY
    • GEA GROUP AG
    • GEBRUDER LODIGE MASCHINENBAU GMBH
    • GLATT GMBH
    • HOSOKAWA MICRON CORPORATION
    • KORSCH AG
    • LB BOHLE MASCHINEN + VERFAHREN GMBH
    • MUNSON MACHINERY COMPANY
    • PFIZER INC
    • SIEMENS HEALTHINEERS
    • SYNTEGON (FORMERLY BOSCH PACKAGING TECHNOLOGY)
    • THERMO FISHER SCIENTIFIC INC
目錄
Product Code: 30916

KEY FINDINGS

The global pharmaceutical continuous manufacturing market is anticipated to register a CAGR of 10.23%, during the studied period of 2021 to 2028. The market growth is facilitated by key drivers, such as, the increasing adoption of pharmaceutical continuous manufacturing systems, the government initiatives for adopting continuous manufacturing systems, the opportunities for development across emerging markets, the rising production of large molecules and biologics, and the increasing healthcare expenditure.

MARKET INSIGHTS

Continuous manufacturing entails an advanced manufacturing approach conducted by employing end-to-end integration of manufacturing subprocesses, along with a substantial level of control strategies.

The growth of the global pharmaceutical continuous manufacturing market is anticipated to be fueled by the opportunities across the untapped and emerging markets, owing to the availability of enhanced pharmaceutical infrastructure, the increased demand for pharmaceutical continuous manufacturing systems, and the growing number of pharmaceutical industries. Moreover, emerging countries' healthcare industry is also augmenting at a considerable rate, given the increased demand for advanced manufacturing systems, as well as notable government investments, in order to improve the healthcare infrastructure.

REGIONAL INSIGHTS

The global pharmaceutical continuous manufacturing market growth is evaluated by studying the Asia Pacific, North America, Europe, and the rest of the Asia Pacific. The Asia Pacific is anticipated to grow with the highest CAGR over the forecast period, owing to factors such as, the augmenting contract research organization (CRO) and contract manufacturing organization (CMO), and growing investments across the region's pharmaceutical and biopharmaceutical industry.

COMPETITIVE INSIGHTS

Although the industry growth of the pharmaceutical continuous manufacturing market is high, the product differentiation is considerably low. Besides, key players are reluctant to divest from their businesses. With a substantial amount of investment involved, the exit barriers are moderately difficult. As a result, the degree of competitive rivalry is projected as moderate to high, over the forecast period.

Some of the key players operating in the market are, Korsch AG, Pfizer Inc, Eli Lilly & Company, Siemens Healthineers, Thermo Fisher Scientific Inc, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. KEY DRIVERS
    • 3.1.1. DEVELOPMENT OPPORTUNITIES IN UNTAPPED EMERGING MARKETS
    • 3.1.2. INCREASED ADOPTION OF PHARMACEUTICAL CONTINUOUS MANUFACTURING SYSTEMS
    • 3.1.3. RISING GOVERNMENT INITIATIVES FOR THE ADOPTION OF CONTINUOUS MANUFACTURING SYSTEMS
    • 3.1.4. RISE IN PRODUCTION OF LARGE MOLECULES AND BIOLOGICS
    • 3.1.5. INCREASE IN THE HEALTHCARE EXPENDITURE
  • 3.2. KEY RESTRAINTS
    • 3.2.1. INCREASING CUSTOMER ANTICIPATIONS
    • 3.2.2. LACK OF DEMAND FOR CONTINUOUS MANUFACTURING SYSTEMS IN UNDERDEVELOPED COUNTRIES

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCE ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. IMPACT OF COVID-19 ON PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET
  • 4.3. REGULATORY FRAMEWORK
  • 4.4. OPPORTUNITY MATRIX
  • 4.5. VENDOR LANDSCAPE
  • 4.6. KEY INVESTMENT INSIGHTS

5. MARKET BY PRODUCT

  • 5.1. INTEGRATED CONTINUOUS SYSTEM
  • 5.2. SEMI-CONTINUOUS SYSTEM
  • 5.3. CONTROL & SOFTWARE

6. MARKET BY APPLICATION

  • 6.1. FINAL DRUG PRODUCT MANUFACTURING
  • 6.2. API MANUFACTURING

7. MARKET BY END-USER

  • 7.1. PHARMACEUTICAL COMPANIES
  • 7.2. CONTRACT MANUFACTURING ORGANIZATIONS
  • 7.3. OTHER END-USERS

8. GEOGRAPHICAL ANALYSIS

  • 8.1. NORTH AMERICA
    • 8.1.1. MARKET SIZE & ESTIMATES
    • 8.1.2. KEY GROWTH ENABLERS
    • 8.1.3. KEY CHALLENGES
    • 8.1.4. KEY PLAYERS
    • 8.1.5. COUNTRY ANALYSIS
      • 8.1.5.1. UNITED STATES
      • 8.1.5.2. CANADA
  • 8.2. EUROPE
    • 8.2.1. MARKET SIZE & ESTIMATES
    • 8.2.2. KEY GROWTH ENABLERS
    • 8.2.3. KEY CHALLENGES
    • 8.2.4. KEY PLAYERS
    • 8.2.5. COUNTRY ANALYSIS
      • 8.2.5.1. GERMANY
      • 8.2.5.2. FRANCE
      • 8.2.5.3. UNITED KINGDOM
      • 8.2.5.4. ITALY
      • 8.2.5.5. RUSSIA
      • 8.2.5.6. BELGIUM
      • 8.2.5.7. POLAND
      • 8.2.5.8. REST OF EUROPE
  • 8.3. ASIA PACIFIC
    • 8.3.1. MARKET SIZE & ESTIMATES
    • 8.3.2. KEY GROWTH ENABLERS
    • 8.3.3. KEY CHALLENGES
    • 8.3.4. KEY PLAYERS
    • 8.3.5. COUNTRY ANALYSIS
      • 8.3.5.1. CHINA
      • 8.3.5.2. INDIA
      • 8.3.5.3. JAPAN
      • 8.3.5.4. AUSTRALIA & NEW ZEALAND
      • 8.3.5.5. SOUTH KOREA
      • 8.3.5.6. THAILAND
      • 8.3.5.7. INDONESIA
      • 8.3.5.8. VIETNAM
      • 8.3.5.9. REST OF ASIA PACIFIC
  • 8.4. REST OF WORLD
    • 8.4.1. MARKET SIZE & ESTIMATES
    • 8.4.2. KEY GROWTH ENABLER
    • 8.4.3. KEY CHALLENGE
    • 8.4.4. KEY PLAYERS
    • 8.4.5. REGIONAL ANALYSIS
      • 8.4.5.1. LATIN AMERICA
      • 8.4.5.2. MIDDLE EAST & AFRICA

9. COMPETITIVE LANDSCAPE

  • 9.1. KEY STRATEGIC DEVELOPMENTS
    • 9.1.1. MERGER & ACQUISITIONS
    • 9.1.2. PRODUCT LAUNCH & DEVELOPMENTS
    • 9.1.3. PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
    • 9.1.4. BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
  • 9.2. COMPANY PROFILE
    • 9.2.1. COPERION GMBH
    • 9.2.2. ELI LILLY & COMPANY
    • 9.2.3. GEA GROUP AG
    • 9.2.4. GEBRUDER LODIGE MASCHINENBAU GMBH
    • 9.2.5. GLATT GMBH
    • 9.2.6. HOSOKAWA MICRON CORPORATION
    • 9.2.7. KORSCH AG
    • 9.2.8. LB BOHLE MASCHINEN + VERFAHREN GMBH
    • 9.2.9. MUNSON MACHINERY COMPANY
    • 9.2.10. PFIZER INC
    • 9.2.11. SIEMENS HEALTHINEERS
    • 9.2.12. SYNTEGON (FORMERLY BOSCH PACKAGING TECHNOLOGY)
    • 9.2.13. THERMO FISHER SCIENTIFIC INC

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - PHARMACEUTICAL CONTINUOUS MANUFACTURING
  • TABLE 2: PROJECTED NATIONAL HEALTHCARE EXPENDITURE, 2021-2028 (IN $ BILLION)
  • TABLE 3: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 4: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 5: GLOBAL INTEGRATED CONTINUOUS SYSTEM MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 6: GLOBAL INTEGRATED CONTINUOUS SYSTEM MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 7: GLOBAL SEMI-CONTINUOUS SYSTEM MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 8: GLOBAL SEMI-CONTINUOUS SYSTEM MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 9: GLOBAL CONTROL & SOFTWARE MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 10: GLOBAL CONTROL & SOFTWARE MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 11: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 12: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 13: GLOBAL FINAL DRUG PRODUCT MANUFACTURING MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 14: GLOBAL FINAL DRUG PRODUCT MANUFACTURING MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 15: GLOBAL API MANUFACTURING MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 16: GLOBAL API MANUFACTURING MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 17: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END-USER, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 18: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END-USER, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 19: GLOBAL PHARMACEUTICAL COMPANIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 20: GLOBAL PHARMACEUTICAL COMPANIES MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 21: GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 22: GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 23: GLOBAL OTHER END-USERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 24: GLOBAL OTHER END-USERS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 25: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 26: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 27: NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 28: NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 29: LEADING PLAYERS OPERATING IN NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET
  • TABLE 30: EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 31: EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 32: LEADING PLAYERS OPERATING IN EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET
  • TABLE 33: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 34: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 35: LEADING PLAYERS OPERATING IN ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET
  • TABLE 36: REST OF WORLD PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 37: REST OF WORLD PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 38: LEADING PLAYERS OPERATING IN REST OF WORLD PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET

LIST OF FIGURES

  • FIGURE 1: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 2: OPPORTUNITY MATRIX
  • FIGURE 3: VENDOR LANDSCAPE
  • FIGURE 4: KEY INVESTMENT INSIGHTS
  • FIGURE 5: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, IN 2020
  • FIGURE 6: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY INTEGRATED CONTINUOUS SYSTEM, 2021-2028 (IN $ MILLION)
  • FIGURE 7: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY SEMI-CONTINUOUS SYSTEM, 2021-2028 (IN $ MILLION)
  • FIGURE 8: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY CONTROL & SOFTWARE, 2021-2028 (IN $ MILLION)
  • FIGURE 9: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, IN 2020
  • FIGURE 10: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY FINAL DRUG PRODUCT MANUFACTURING, 2021-2028 (IN $ MILLION)
  • FIGURE 11: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY API MANUFACTURING, 2021-2028 (IN $ MILLION)
  • FIGURE 12: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END-USER, IN 2020
  • FIGURE 13: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PHARMACEUTICAL COMPANIES, 2021-2028 (IN $ MILLION)
  • FIGURE 14: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY CONTRACT MANUFACTURING ORGANIZATIONS, 2021-2028 (IN $ MILLION)
  • FIGURE 15: GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY OTHER END-USERS, 2021-2028 (IN $ MILLION)
  • FIGURE 16: NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 17: UNITED STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 18: CANADA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 19: EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 20: GERMANY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 21: FRANCE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 22: UNITED KINGDOM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 23: ITALY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 24: RUSSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 25: BELGIUM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 26: POLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 27: REST OF EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 28: ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 29: CHINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 30: INDIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 31: JAPAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 32: AUSTRALIA & NEW ZEALAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 33: SOUTH KOREA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 34: THAILAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 35: INDONESIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 36: VIETNAM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 37: REST OF ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 38: REST OF WORLD PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, REGIONAL OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 39: LATIN AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 40: MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, 2021-2028 (IN $ MILLION)